2005 Publications From the Smith Breast Center
November – December 2005
Hutchins LF, Green SJ, Ravdin PM, Lew D, Martino S, Abeloff M, Lyss AP, Allred DC, Rivkin SE, Osborne CK. Randomized, controlled trial of Cyclophosphamide, Methotrexate, and Fluorouracil versus Cyclophosphamide, Doxorubicin, and Fluorouracil with and without tamoxifen for high-risk, node-negative breast cancer: Treatment results of Intergroup Protocol INT-0102. J Clin Oncol 23:8313-8321, 2005
Mohsin S, Allred D, Osborne CK, Cruz A, Otto P, Chew H, Clark G, Elledge R. Morphologic and immunophenotypic markers as surrogate endpoints of tamoxifen effect for prevention of breast cancer. Breast Cancer Res Treat 94:205-211, 2005.
Brown PH, Rashid A. Cancer prevention: The importance of accurate risk assessment. Cancer Epidemiol, Biomarkers & Prevention 14:1357-1358, 2005.
Lu C, Shen Q, Kim H, Hilsenbeck S, Brown P. cFos is critical for MCF 7 breast cancer cell growth. Oncogene 24:6616-6524, 2005.
Wu K, Kim H, Caesar K, U T, Bissonnette RP, Lamph WW, Brown PH. Receptor-selective retinoids inhibit normal and malignant breast cell growth predominantly through a G1 cell cycle blockade. Breast Cancer Research and Treatment, on-line first DOI: 10.1007/s10549-005-9071-1, 2005.
Shen Q, Brown P. Transgenic mouse models for the prevention of breast cancer. Mutation Research 576:93-110, 2005
Cleator S, Tsimelzon A, Ashworth A, Dowsett M, Dexter T, Powles T, Hilsenbeck S, Wong H, Osborne CK, O’Connell P, Chang JC. Gene expression patterns for doxorubicin (Adriamycin) and cyclophosphamide (Cytoxan) (AC) response and resistance. Breast Cancer Research and Treatment 2005 (on-line first, www.springerlink.com DOI:10.1007/s10549-005-9099-7)
Tham YL, Gomez LF, Mohsin S, Gutierrez MC, Weiss H, Hilsenbeck SG, Elledge RM, Chamness GC, Osborne CK, Allred DC, Chang JC. Clinical response to neoadjuvant docetaxel predicts improved outcome in patients with large locally advanced breast cancers. Clinical Cancer Research and Treatment 94:279-284, 2005.
Friedman LC, Kalidas M, Elledge R, Chang J, Romero C, Husain I, Dulay MF, Liscum KR. Optimism, social support and psychosocial functioning among women with breast cancer. Psycho-Oncology 2005 (in press) (on- line www.interscience.wiley.com DOI 10.1002/pon992).
Chang JC, Weiss H, Mohsin S. Apoptosis induction by the core biopsy procedure. Journal of Clinical Oncology 23:7240, 2005.
Osborne CK, Schiff R, Arpino G, Lee A, Hilsenbeck SG. Endocrine responsiveness: Understanding how progesterone receptor can be used to select endocrine therapy. Breast 14:458-465 2005.
Schiff R, Massarweh SA, Shou J, Bharwani L, Arpino G, Rimawi M, Osborne CK. Advanced concepts in estrogen receptor biology and breast cancer endocrine resistance: implicated role of growth factor signaling and estrogen receptor coregulators. Cancer Chemother Pharmacol 56S(7): 10-20, 2005.
Behbod F, Xian W, Shaw CA, Hilsenbeck SG, Tsimelzon A, Rosen JM. Transcriptional profiling of mammary gland side population cells. Stem Cells Express, first published online Nov 10, 2005.
Singh RR, Barnes CJ, Talukder AH, Fuqua SA, Kumar R: Negative regulation of estrogen receptor alpha transactivation functions by LIM Domain Only 4 protein. Cancer Res 65:10594-10601, 2005.
September – October 2005
Lu C, Shen Q, DuPre E, Kim H, Hilsenbeck S, Brown PH. cFos is critical for MCF-7 breast cancer cell growth. Oncogene 24:6516-6524, 2005.
Martin M.D., Hilsenbeck SG, Mohsin SK, Hopp TA, Clark GM, Osborne CK, Allred DC, O'Connell P. Breast tumors that overexpress nuclear metastasis-associated 1 (MTA1) protein have high recurrence risks but enhanced responses to systemic therapies. Breast Cancer Res Treat [Epub] Oct 22:1-3, 2005 .
Myers GD, Krance RA, Weiss H, Kuehnle I, Demmler G, Heslop HE, Bollard CM. Adenovirus infection rates in pediatric recipients of alternate donor allogeneic bone marrow transplants receiving either antithymocyte globulin (ATG) or alemtuzumab (Campath). Bone Marrow Transpl, 26 September, 2005.
Arpino G, Ciocca DR, Weiss H, Allred DC, Daguerre P, Vargas-Roig L, Leuzzi M, Gago F, Elledge R, Mohsin SK. Predictive value of apoptosis, proliferation, HER-2, and topoisomerase IIα for anthracycline chemotherapy in locally advanced breast cancer. Breast Cancer Res Treat. 92:69-75, 2005.
Arpino G, Weiss H, Lee AV, Schiff R, De Placido S, Osborne CK, Elledge RM. Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance. J Natl Cancer Inst 97:1254-1261, 2005.
Chang JC, Weiss H, Mohsin S. Apoptosis induction by the core biopsy procedure. J Clin Oncol 23:7240-7242, 2005.
Arpino G, Laucirica R, Elledge R. Premalignant and in situ breast disease: biology and clinical implications. Ann Intern Med143:446-57: 2005.
Cui X, Schiff R, Arpino G, Osborne CK, Lee AV. Biology of progesterone receptor loss in breast cancer and its implications for endocrine therapy. J Clin Oncol 23:7721-35, 2005.
Jiang S, Meyer R, Kang K, Osborne CK, Wong J, Oesterreich S. Scaffold attachment factor SAFB1 suppresses ERα-mediated transcription in part via interaction with N-CoR. Mol Endocrinol Sep 29, 2005.
Poola I, Fuqua SAW, DeWitty RL, Abraham J, Marshallack JJ, Liu A. ERα-negative breast cancer tissues express significant levels of estrogen independent transcription factors, ERβ1 and ERβ5: Potential molecular targets for chemoprevention. Clinical Cancer Research 11:7579-7582, 2005.
July – August 2005
Howell A, Pippen J, Elledge RM, Mauriac L, Vergote I, Jones SE, Come SE, Osborne CK, Robertson JFR. Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma. Cancer 104:236-239: 2005.
Lu C, Shen Q, Dupre E, Kim H, Hilsenbeck S, Brown PH. cFos is critical for MCF-7 breast cancer cell growth. Oncogene [Epub July 18, 2005].
May – June 2005
Carboni JM, Lee AV, Hadsell DL, Rowley BR, Lee FY, Bol DK, Camuso AE, Gottardis M, Greer AF, Ho CP, Hurlburt W, Li A, Saulnier M, Velaparthi U, Wang C, Wen ML, Westhouse RA, Wittman M, Zimmermann K, Rupnow BA, Wong TW. Tumor development by transgenic expression of a constitutively active insulin-like growth factor I receptor. Cancer Res. 65:3781-7, 2005.
Zhang X, Podsypanina K, Huang S, Mohsin SK, Chamness GC, Hatsell S, Cowin P, Schiff R, Li Y. Estrogen receptor positivity in mammary tumors of Wnt-1 transgenic mice isinfluenced by collaborating oncogenic mutations. Oncogene. 24:4220-31, 2005.PMID: 15824740
March – April 2005
Chen DT, Rosenstein DL, Muthappan P, Hilsenbeck SG, Miller FG, Emanuel EJ, Wendler D. Research with stored biological samples: what do research participants want? Arch Intern Med 165(6):652-655, 2005.
Kong G, Kim HT, Wu K, Denardo D, Hilsenbeck SG, Xu XC, Lamph WW, Bissonnette R, Dannenberg AJ, Brown PH. The retinoid X receptor-selective retinoid, LGD1069, down-regulates cyclooxygenase-2 expression in human breast cells through transcription factor crosstalk: implications for molecular-based chemoprevention. Cancer Res 65(8):3462-3469, 2005.
Fuqua SAW, Cui Y, Lee AV, Osborne CK, Horwitz KR: Insights into the role of progesterone receptors in breast cancer. J Clin Oncol 23:931-932, 2005.
Jeong J-W, Lee KY, Kwak I, White LD, Hilsenbeck SG, Lydon JP, DeMayo FJ. Identification of murine uterine genes regulated in a ligand-dependent manner by the progesterone receptor. Endocrinology, April 21, 2005 .
Ivanova M, Dobrzycka KM, Jiang S, Michaelis K, Meyer R, Kang K, Adkins B, Barski OA, Zubairy S, Divisova J, Lee AV, Oesterreich S. Scaffold attachment factor B1 functions in development, growth, and reproduction. Mol Cell Biol 25:2995-3006, 2005.
Lee S, Mohsin SK , Weiss H, Medina D, Allred DC : Apocrine metaplasia and the development of ER-negative breast cancer. Mod Pathol 18 (Suppl 1):40A(abst# 171, 2005.
Genty C, Mao S, Mohsin SK , Allred DC : Quantitative ELISA-like IHC (QUELI) of FFPE Tissue. Mod Pathol 18 (Suppl 1):329A (abst #1528), 2005.
Mohsin SK , Arbab F, Allred DC : Are synchronous atypical ductal hyperplasia and atypical lobular hyperplasia (which are common) genetically related? Mod Pathol 18 (Suppl 1): 44A(abst #189), 2005.
Mohsin S, Weiss H, Gutierrez MC, Chamness G, Schiff R, DiGiovanna M, Hilsenbeck S, Osborne CK, Allred DC, Elledge R, Chang J. Neoadjuvant trastuzumab induces apoptosis in primary breast cancers. J Clin Oncol 23(11); 2460-2468: 2005
January – February 2005
Denardo DG, Kim H-T, Hilsenbeck S, Cuba V, Tsimelzon A, Brown PH. Global gene expression analysis of estrogen receptor transcription factor cross talk in breast cancer: identification of estrogen-induced/activator protein-1-dependent genes. Mol Endocrinol 19:362-378, 2005.
Jatoi I, Tsimelzon A, Weiss H, Clark GM, Hilsenbeck SG. Hazard rates of recurrence following diagnosis of primary breast cancer. Breast Cancer Res Treat 89:173-178, 2005.
Mohsin SK, Weiss HL, Gutierrez MC, Chamness GC, Schiff R, DiGiovanna MP, Wang CX, Hilsenbeck SG, Osborne CK, Allred DC, Elledge R, Chang JC. Neoadjuvant trastuzumab induces apoptosis in primary breast cancers. J Clin Oncol 23: 2005.
Chang JC, Hilsenbeck SG, Fuqua SA. Genomic approaches in the management and treatment of breast cancer. Br J Cancer 92:618-624, 2005.
Chang JC, Wooten EC, Tsimelzon A, Hilsenbeck SG, Gutierrez MC, Tham YL, Kalidas M, Elledge R, Mohsin S, Osborne CK, Chamness GC, Allred DC, Lewis MT, Wong H, O’Connell P. Patterns of resistance and incomplete response to docetaxel (Taxotere) by gene expression profiling in breast cancer patients. J Clin Oncol 23:1169-77, 2005.
Fuqua SAW, Cui Y, Lee AV, Osborne CK, Horwitz KR. Insights into the role of progesterone receptors in breast cancer. J Clin Oncol 23:931-932, 2005.
Nichols HB, Trentham-Dietz A, Love RR, Hampton JM, Hoang Anh PT, Allred DC, Mohsin SK, Newcomb PA. Differences in breast cancer risk factors by tumor marker subtypes among premenopausal Vietnamese and Chinese women. Cancer Epidemiol Biomarkers Prev 14:41-47, 2005.
Mohsin SK, Weiss HL, Gutierrez MC, Chamness GC, Schiff R, Digiovanna MP, Wang CX, Hilsenbeck SG, Osborne CK, Allred DC, Elledge R, Chang JC. Neoadjuvant trastuzumab induces apoptosis in primary breast cancers. J Clin Oncol 2005 [Epub ahead of print Feb 14]
Gao X, Mohsin SK, Gatalica Z, Fu G, Sharma P, Nawaz Z. Decreased expression of E6-AP in breast and prostate carcinomas. Endocrinol 2005